Aclaris Therapeutics, Inc. (ACRS)
A
Pipeline Grade
Financial Position (from SEC Filings)
$28.7M
Cash & Equivalents
$18.2M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$779M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
HYDROGEN PEROXIDE
ESKATA |
NDA | Advanced Solid Tumor, Advanced Solid Tumor Malignancies, Alopecia, Alopecia Areata, Alopecia Totalis, Alopecia Totalis (AT), Alopecia Universalis, Alopecia Universalis (AU), Androgenetic Alopecia, Atopic, Atopic Dermatitis, Cancer of the Pancreas, Common Wart, Common Warts, Cryopyrin-Associated Periodic Syndrome, Dermatitis, Dermatosis Papulosa Nigra, Eczema, Hidradenitis Suppurativa, Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Psoriatic Arthritis, Rheumatoid Arthritis, Rosacea, Seborrheic Keratosis, Seborrheic Keratosis (SK), Vitiligo |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase2 Readout | — |
| 2027-06-30 | Phase1 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06374459 | Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Br... | PHASE2 | Recruiting | 152 |
| NCT07011706 | ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis | PHASE2 | Active Not Recruiting | 110 |
| NCT06648434 | MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma | PHASE1 | Recruiting | 51 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.